Intriguingly, the clinical success of IL-4 pathway inhibitors (such as dupilumab, which blocks IL-4Rα, or various JAK inhibitors) in managing Th2-driven inflammatory diseases like atopic dermatitis and asthma provides a compelling precedent. The gene discussed is IL4R; the disease is asthma.